These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37693224)

  • 41. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. (11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Zhang S; Smailagic N; Hyde C; Noel-Storr AH; Takwoingi Y; McShane R; Feng J
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010386. PubMed ID: 25052054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Visual contrast sensitivity is associated with the presence of cerebral amyloid and tau deposition.
    Risacher SL; WuDunn D; Tallman EF; West JD; Gao S; Farlow MR; Brosch JR; Apostolova LG; Saykin AJ
    Brain Commun; 2020; 2(1):fcaa019. PubMed ID: 32309804
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.
    Li TR; Yao YX; Jiang XY; Dong QY; Yu XF; Wang T; Cai YN; Han Y
    Alzheimers Res Ther; 2022 May; 14(1):66. PubMed ID: 35550625
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Accuracy of the Brief Cognitive Screening Battery for diagnosing Alzheimer's disease defined by cerebrospinal fluid biomarkers and AT(N) classification: a case-control study.
    Peles PRH; Salvador LS; Souza LC; Caramelli P
    Arq Neuropsiquiatr; 2022 Jan; 80(1):23-29. PubMed ID: 34816970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Amyloid-β Positivity Predicts Cognitive Decline but Cognition Predicts Progression to Amyloid-β Positivity.
    Elman JA; Panizzon MS; Gustavson DE; Franz CE; Sanderson-Cimino ME; Lyons MJ; Kremen WS;
    Biol Psychiatry; 2020 May; 87(9):819-828. PubMed ID: 32067693
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blood Derived Amyloid Biomarkers for Alzheimer's Disease Prevention.
    Udeh-Momoh C; Zheng B; Sandebring-Matton A; Novak G; Kivipelto M; Jönsson L; Middleton L
    J Prev Alzheimers Dis; 2022; 9(1):12-21. PubMed ID: 35098969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tau accumulation and its spatial progression across the Alzheimer's disease spectrum.
    St-Onge F; Chapleau M; Breitner JCS; Villeneuve S; Pichet Binette A
    Brain Commun; 2024; 6(1):fcae031. PubMed ID: 38410618
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression.
    Huijbers W; Mormino EC; Schultz AP; Wigman S; Ward AM; Larvie M; Amariglio RE; Marshall GA; Rentz DM; Johnson KA; Sperling RA
    Brain; 2015 Apr; 138(Pt 4):1023-35. PubMed ID: 25678559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High performance plasma amyloid-β biomarkers for Alzheimer's disease.
    Nakamura A; Kaneko N; Villemagne VL; Kato T; Doecke J; Doré V; Fowler C; Li QX; Martins R; Rowe C; Tomita T; Matsuzaki K; Ishii K; Ishii K; Arahata Y; Iwamoto S; Ito K; Tanaka K; Masters CL; Yanagisawa K
    Nature; 2018 Feb; 554(7691):249-254. PubMed ID: 29420472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mayo normative studies: A conditional normative model for longitudinal change on the Auditory Verbal Learning Test and preliminary validation in preclinical Alzheimer's disease.
    Alden EC; Lundt ES; Twohy EL; Christianson TJ; Kremers WK; Machulda MM; Jack CR; Knopman DS; Mielke MM; Petersen RC; Stricker NH
    Alzheimers Dement (Amst); 2022; 14(1):e12325. PubMed ID: 35860792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study.
    Souchet B; Michaïl A; Heuillet M; Dupuy-Gayral A; Haudebourg E; Pech C; Berthemy AA; Autelitano F; Billoir B; Domoto-Reilly K; Fowler C; Grabowski T; Jayadev S; Masters CL; Braudeau J
    J Prev Alzheimers Dis; 2024; 11(3):567-581. PubMed ID: 38706273
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnostic value of digital clock drawing test in comparison with CERAD neuropsychological battery total score for discrimination of patients in the early course of Alzheimer's disease from healthy individuals.
    Müller S; Herde L; Preische O; Zeller A; Heymann P; Robens S; Elbing U; Laske C
    Sci Rep; 2019 Mar; 9(1):3543. PubMed ID: 30837580
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sex differences in episodic memory in early midlife: impact of reproductive aging.
    Rentz DM; Weiss BK; Jacobs EG; Cherkerzian S; Klibanski A; Remington A; Aizley H; Goldstein JM
    Menopause; 2017 Apr; 24(4):400-408. PubMed ID: 27824681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Comparison of Cross-Sectional and Longitudinal Methods of Defining Objective Subtle Cognitive Decline in Preclinical Alzheimer's Disease Based on Cogstate One Card Learning Accuracy Performance.
    Pudumjee SB; Lundt ES; Albertson SM; Machulda MM; Kremers WK; Jack CR; Knopman DS; Petersen RC; Mielke MM; Stricker NH
    J Alzheimers Dis; 2021; 83(2):861-877. PubMed ID: 34366338
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.